Skip to main content
SpringerLink
Log in

Lokalisation von Bevacizumab in der Netzhaut von Affen nach einer intravitrealen Bevacizumab-Injektion

Localisation of bevacizumab in the monkey retina after an intravitreal injection of Avastin®

  • Originalien
  • Published:
Der Ophthalmologe Aims and scope Submit manuscript

Zusammenfassung

Hintergrund

Es sollte untersucht werden, inwiefern nach der intravitrealen Injektion von Avastin® der VEGF-Antikörper Bevacizumab in der Lage ist, die Retina von Primaten zu durchdringen.

Material und Methoden

Affen (Macaca fascicularis) wurden intravitreal mit radioaktiv markiertem und freiem Avastin® injiziert. Die Tiere wurden an den Tagen 1, 4, 7 bzw. 14 nach der Injektion getötet, um die Augen histologisch und immunhistochemisch zu untersuchen. Außerdem wurden an mehreren Tagen Blutproben entnommen.

Ergebnisse

In den funduskopischen Aufnahmen konnten keine pathologischen Änderungen während der Laufzeit der Versuche festgestellt werden. Mittels der Immunhistochemie konnte Bevacizumab bereits einen Tag nach der Injektion in der Aderhaut und in den inneren Schichten der Retina nachgewiesen werden. In der Fovea konnte Bevacizumab schneller eindringen als in der übrigen Netzhaut. Bevacizumab war auch in den Photorezeptoren und in den Blutgefäßen anzutreffen. Bei der Verwendung von mit 125I markiertem Avastin konnte bereits 1 Tag nach der Injektion Radioaktivität im Blutserum festgestellt werden.

Schlussfolgerung

Die Ergebnisse zeigen, dass das Bevacizumab-Molekül nach der intravitrealen Injektion von Avastin® die Retina durchdringen kann. Dabei findet eine aktive Aufnahme in die retinalen Zellen statt.

Abstract

Background

The aim was to investigate to what extent the vascular endothelial growth factor (VEGF) antibody bevacizumab is able to penetrate the retina in primates after an intravitreal injection of Avastin.

Material and Methods

Monkeys (Macaca fascicularis) were injected intravitreally with radioactively labelled and free Avastin. The animals were sacrificed 1, 4, 7, or 14 days after the injection, and the eyes were examined histologically and immunohistochemically. Blood samples were also taken on several days.

Results

In the fundoscopic images, no pathologic changes could be found during the experiment. Using immunohistochemistry, bevacizumab was found in the choroid and the inner layers of the retina 1 day after the injection. Bevacizumab penetrated more quickly in the fovea than in the rest of the retina. It was also encountered in the photoreceptors and blood vessels. When 125I-labelled Avastin was used, radioactivity could be determined in the blood serum 1 day after the injection.

Conclusion

The results show that the bevacizumab molecule can penetrate the retina after intravitreal injection of Avastin. However, there is an active uptake in the retinal cells.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Abb. 1
Abb. 2
Abb. 3
Abb. 4
Abb. 5

Literatur

  1. Feiner L, Barr EE, Shui YB et al. (2006) Safety of intravitreal injection of bevacizumab in rabbit eyes. Retina 26: 882–888

    Article  PubMed  Google Scholar 

  2. Heiduschka P, Fietz H, Hofmeister S et al. (2007) Penetration of bevacizumab through the retina after intravitreal injection in the monkey. Invest Ophthalmol Vis Sci 48: 2814–2823

    Article  PubMed  Google Scholar 

  3. Heiduschka P, Julien S, Hofmeister S et al. (2008) Bevacizumab (Avastin) does not harm retinal function after intravitreal injection as shown by electroretinography in adult mice. Retina 28: 46–55

    Article  PubMed  Google Scholar 

  4. Inan UU, Avci B, Kusbeci T et al. (2007) Preclinical safety evaluation of intravitreal injection of full-length humanized vascular endothelial growth factor antibody in rabbit eyes. Invest Ophthalmol Vis Sci 48: 1773–1781

    Article  PubMed  Google Scholar 

  5. Klettner A et al. (2007) DOG-Abstract SO.07.10; ePub ahead of Print bei IOVS)

  6. Lüke M, Warga M, Ziemssen F et al. (2006) Effects of bevacizumab on retinal function in isolated vertebrate retina. Br J Ophthalmol 90: 1178–1182

    Article  PubMed  Google Scholar 

  7. Manzano RPA, Peyman GA, Khan P et al. (2006) Testing intravitreal toxicity of bevacizumab (Avastin). Retina 26: 257–261

    Article  PubMed  Google Scholar 

  8. Maturi RK, Bleau LA, Wilson DL (2006) Electrophysiologic findings after intravitreal bevacizumab (Avastin) treatment. Retina 26: 270–274

    Article  PubMed  Google Scholar 

  9. Mordenti J, Cuthbertson RA, Ferrara N et al. (1999) Comparisons of the intraocular tissue distribution, pharmacokinetics, and safety of 125I-labeled full-length and Fab antibodies in rhesus monkeys following intravitreal administration. Toxicol Pathol 27: 536–544

    Article  PubMed  CAS  Google Scholar 

  10. Moschos MM, Brouzas D, Apostolopoulos M et al. (2007) Intravitreal use of bevacizumab (Avastin) for choroidal neovascularization due to ARMD: a preliminary multifocal-ERG and OCT study. Multifocal-ERG after use of bevacizumab in ARMD. Doc Ophthalmol 114: 37–44

    Article  PubMed  Google Scholar 

  11. Pai SA, Shetty R, Vijayan PB et al. (2007) Clinical, anatomic, and electrophysiologic evaluation following intravitreal bevacizumab for macular edema in retinal vein occlusion. Am J Ophthalmol 143: 601–606

    Article  PubMed  CAS  Google Scholar 

  12. Peters S, Heiduschka P, Julien S et al. (2007) Ultrastructural findings in the primate eye after intravitreal injection of bevacizumab. Am J Ophthalmol 143: 995–1002

    Article  PubMed  CAS  Google Scholar 

  13. Schraermeyer U, Henke-Fahle S, Grisanti S et al. (2006) Evidence for transport of bevacizumab (Avastin) through the retina by Müller cells in rabbits. Invest Ophthalmol Vis Sci 47: E-Abstract 4169

    Google Scholar 

  14. Shah MA, Ilson D, Kelsen DP (2005). Thrombembolic events in gastric cancer: high incidence in patients receiving irinotecan- and bevacizumab-based therapy. J Clin Oncol 23: 2574–2576

    Article  PubMed  Google Scholar 

  15. Shahar J, Avery RL, Heilweil G et al. (2006) Electrophysiologic and retinal penetration studies following intravitreal injection of bevacizumab (Avastin). Retina 26: 262–269

    Article  PubMed  Google Scholar 

  16. Shetty R, Pai SA, Vincent A et al. (2008) Electrophysiological and structural assessment of the central retina following intravitreal injection of bevacizumab for treatment of macular edema. Doc Ophthalmol 116: 129–35

    Article  PubMed  Google Scholar 

  17. Ziemssen F, Lüke M, Messias A et al. (2008) Safety monitoring in bevacizumab (Avastin) treatment: retinal function assessed by psychophysical (visual fields, colour vision) and electrophysiological (ERG/EOG) tests in two subgroups of patients. Int Ophthalmol 28: 101–109

    Article  PubMed  Google Scholar 

Download references

Interessenkonflikt

Der korrespondierende Autor gibt an, dass kein Interessenkonflikt besteht.

Author information

Authors and Affiliations

  1. Sektion für experimentelle vitreoretinale Chirurgie, Tübingen, Schleichstraße 12/1, 72076, Tübingen, Deutschland

    U. Schraermeyer & P. Heiduschka

  2. Department für Augenheilkunde, Universitätsaugenklinik Tübingen, Tübingen, Deutschland

    K.U. Bartz-Schmidt

Authors
  1. U. Schraermeyer
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. P. Heiduschka
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. K.U. Bartz-Schmidt
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to U. Schraermeyer.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Schraermeyer, U., Heiduschka, P. & Bartz-Schmidt, K. Lokalisation von Bevacizumab in der Netzhaut von Affen nach einer intravitrealen Bevacizumab-Injektion. Ophthalmologe 106, 619–624 (2009). https://doi.org/10.1007/s00347-008-1835-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00347-008-1835-7

Schlüsselwörter

Keywords

Search

Navigation